Department of Neonatology, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany.
Early Hum Dev. 2010 Feb;86(2):87-92. doi: 10.1016/j.earlhumdev.2009.12.009. Epub 2010 Feb 12.
To compare neurodevelopmental results in very low birth weight (VLBW) infants two years after successful or failed cyclooxygenase inhibitor treatment with either indomethacin or ibuprofen for a haemodynamically significant patent ductus arteriosus (hsPDA).
We retrospectively evaluated closure rates and outcome parameters of VLBW infants with hsPDA 89 of whom were treated with indomethacin and 93 with ibuprofen.
Indomethacin and ibuprofen therapy groups did not differ in their baseline clinical profile (median gestational age 26.0 and 26.2wksd) in early (median CRIB 6 and 5, respiratory distress >2 degrees in 36 and 34 infants) and late morbidities (intraventricular hemorrhage >2 degrees in 9 and 10 infants, bronchopulmonary dysplasia in 31 and 27 infants, 80 and 85 survivors), PDA closure rates (63 and 58%) or neurodevelopmental outcome. The therapy failure group (54 infants) was characterized by lower median gestational age (25.0wksd) and higher mortality (17%). No differences were found in the neurodevelopmental outcome of the surviving infants with ligation as compared to the survivors with successful pharmacological closure of the PDA at 24months corrected age.
Use of either ibuprofen or indomethacin for closure of a hsPDA did not influence two year neurodevelopmental outcomes in VLBW infants.
比较使用非甾体类抗炎药（NSAIDs）吲哚美辛或布洛芬成功或失败治疗患有血流动力学显著动脉导管未闭（hsPDA）的极低出生体重儿（VLBW）在 hsPDA 治疗后 2 年的神经发育结果。
我们回顾性评估了 89 例接受吲哚美辛治疗和 93 例接受布洛芬治疗的患有 hsPDA 的 VLBW 婴儿的闭合率和结局参数。
吲哚美辛和布洛芬治疗组在基线临床特征（中位胎龄 26.0 和 26.2 周）、早期（中位 CRIB 评分 6 和 5，36 和 34 例患儿存在 2 度以上呼吸窘迫）和晚期并发症（9 和 10 例患儿存在 2 度以上脑室内出血，31 和 27 例患儿存在支气管肺发育不良，80 和 85 例患儿存活）、PDA 闭合率（63%和 58%）或神经发育结局方面均无差异。治疗失败组（54 例）的特征为中位胎龄较低（25.0 周）和死亡率较高（17%）。在 24 个月校正年龄时，与 PDA 成功药物闭合的存活婴儿相比，结扎存活婴儿的神经发育结局无差异。
使用布洛芬或吲哚美辛治疗 hsPDA 并不影响 VLBW 婴儿 2 年的神经发育结局。
